Alltrna

Alltrna is a biotechnology company focused on unlocking transfer RNA (tRNA) biology and developing tRNA-based therapeutics to regulate protein production and treat disease. Founded in 2018 by Flagship Pioneering, Alltrna has built a platform that incorporates artificial intelligence and machine learning tools to design, modify, produce, and deliver engineered tRNA molecules with therapeutic potential. The company's initial focus is on developing treatments for "Stop Codon Disease," which encompasses thousands of rare and common genetic disorders caused by premature termination codons (PTCs) that result in truncated or non-functional proteins. Alltrna's engineered tRNAs are designed to read through these PTC mutations and restore full-length protein production, potentially treating multiple diseases with a single therapy. In May 2023, Alltrna presented proof-of-concept data demonstrating that its platform could significantly increase engineered tRNA activity and restore full-length protein expression in cellular and animal models of PTC-driven diseases. The company's approach aims to address approximately 30 million patients worldwide affected by Stop Codon Disease. In August 2023, Alltrna raised USD 109 million in Series B financing to advance its platform and first drug candidates toward clinical studies.